For Healthcare Professionals

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

clipboard-pencil

About the study

This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease severity.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Written informed assent and parental permission (age as per local law) obtained at screening before any assessment is performed.
  2. Must be 6 to less than 18 years of age at the time of randomization
  3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.
  4. Subject being regarded by the investigator to be a candidate for systemic therapy.

EXCLUSION CRITERIA

  1. Forms of psoriasis other than chronic plaque-type active at randomization
  2. Drug-induced psoriasis
  3. Ongoing use of prohibited treatments
  4. Female subjects of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and for 16 weeks after stopping study treatment
  5. Pregnant or nursing (lactating) females
  6. Subjects with total WBC count <2,500/μL, or platelets <100,000/μL or neutrophils <1,500/μL or hemoglobin <8.5 g/dL at screening
  7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-888-669-6682Email iconEmail Study Center

Study’s details


Contition

Moderate to Severe Chronic Plaque-type Psoriasis

Age

6+

Phase

Phase 3

Participants needed

84

Est. Completion Date

Sep 2023

Treatment type

Interventional


Sponsor

Novartis

ClinicalTrials.gov identifier

NCT03668613

Study number

CAIN457A2311

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.